NCT00293111 - Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

October 31, 2003

Conditions

Multiple Myeloma

Interventions

DRUG

SDX-101 (R-Etodolac)

Trial Locations (8)

Roswell Park Cancer Institute, Buffalo

University of Pittsburgh Cancer Institute, Pittsburgh

Johns Hopkins School of Medicine, Baltimore

University of North Carolina at Chapel Hill, Chapel Hill

Emory University School of Medicine, Atlanta

H. Lee Moffitt Cancer Center, Tampa

Cleveland Clinic Foundation, Cleveland

MD Anderson Cancer Center, Houston